DNMT1 and acute myeloid leukemia: The studies reported before showed that miRNAs were significant during AML progression and the occurrence of drug resistance; therefore, targeting the miRNAs-DNMT1 axis will be a promising strategy to treat AML with poor response to traditional chemotherapy.